Steward Health Care System

Return to Results

A Two Week Double-Blind Placebo-Controlled Crossover Study To Compare The Efficacy And Safety Of A Pregabalin/PF-00489791 Combination Versus Pregabalin Alone In Patients With Post-Herpetic Neuralgia

new search

Trial Conditions
  • Postherpetic Neuralgia
What is the purpose of this trial?

Pregabalin is an alpha-2 delta ligand approved for the treatment of neuropathic pain, however, not all patients will respond to this drug. This study will compare the efficacy of pregabalin when administered with an experimental drug PF-00489791, in patients with post-herpetic neuralgia. The efficacy of this combination will be compared to pregabalin alone.

Date & Status

Completed

Who can Participate?

Eligibility

Ages:
18 and older

Gender:
Both

Eligibility

Inclusion Criteria:

- Male or female of non-childbearing potential

- Pain present for more than 3 months after healing of herpes zoster skin rash

- VAS score of >=40mm at screening and baseline visits

Exclusion Criteria:

- Patients with pain conditions which might impair the assessment of postherpetic
neuralgia

- Skin conditions in the affected dermatome that could alter sensation other than
postherpetic neuralgia

- History or diagnosis of DSM IV major depressive disorder

Gender: Both
Steward Physician(s)
  • Pfizer CT.gov Call Center
Trial Interventions
Drug
  • pregabalin
  • pregabalin/PF-00489791
  • Placebo
Physician Researcher

Investigator Name:

  • Pfizer CT.gov Call Center

Other Information

Sponsor: Pfizer
Phase: Phase 2
Trial ID: NCT00599638
Volunteers:  Not Accepting Healthy Volunteers

new search

Connect with Steward

Visit Our Twitter Feed Visit Our Facebook Page Email This Page Print This Page

Subscribe to our patient e-newsletter

Copyright © 2014 Steward Health Care
Connect Healthcare Panacea CMS Solutions